Elanco Animal Health (ELAN) Income from Continuing Operations (2017 - 2026)
Elanco Animal Health (ELAN) reported Income from Continuing Operations of 57000000.0 for Q1 2026, down 14.93% on a YoY basis from 67000000.0 in Q1 2025, and up 120.65% sequentially from 276000000.0 in Q4 2025.
Elanco Animal Health (ELAN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Elanco Animal Health (ELAN) has 10 years of Income from Continuing Operations data on file, last reported at 57000000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 14.93% year-over-year to 57000000.0; the trailing twelve-month figure through Mar 2026 stood at 242000000.0 (down 164.88% YoY), and the FY2025 full-year result was 232000000.0, down 168.64% from the prior year.
- Income from Continuing Operations advanced to 57000000.0 in Q1 2026, from 276000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 364000000.0 in Q3 2024 to a low of 1096000000.0 in Q3 2023.
- A 5-year average of 67411764.71 and a median of 10000000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations surged 179.69% in 2022 and tumbled 3350.0% in 2025, its largest moves.
- Tracing ELAN's Income from Continuing Operations over 5 years: stood at 54000000.0 in 2022, then tumbled by 161.11% to 141000000.0 in 2023, then soared by 94.33% to 8000000.0 in 2024, then plunged by 3350.0% to 276000000.0 in 2025, then jumped by 120.65% to 57000000.0 in 2026.
- Business Quant data shows ELAN's Income from Continuing Operations at 57000000.0 in Q1 2026, 276000000.0 in Q4 2025, and 34000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | -22.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57.00 Mn |
| Dec 31, 2025 | -276.00 Mn |
| Sep 30, 2025 | -34.00 Mn |
| Jun 30, 2025 | 11.00 Mn |
| Mar 31, 2025 | 67.00 Mn |
| Dec 31, 2024 | -8.00 Mn |
| Sep 30, 2024 | 364.00 Mn |
| Jun 30, 2024 | -50.00 Mn |
| Mar 31, 2024 | 32.00 Mn |
| Dec 31, 2023 | -141.00 Mn |
| Sep 30, 2023 | -1.10 Bn |
| Jun 30, 2023 | -97.00 Mn |
| Mar 31, 2023 | 103.00 Mn |
| Dec 31, 2022 | -54.00 Mn |
| Sep 30, 2022 | -65.00 Mn |
| Jun 30, 2022 | -10.00 Mn |
| Mar 31, 2022 | 51.00 Mn |
| Dec 31, 2021 | -105.00 Mn |
| Sep 30, 2021 | -108.00 Mn |
| Jun 30, 2021 | -206.00 Mn |